Comparative Long-Term Outcomes of Vedolizumab and TNF Inhibitors in Patients with Ulcerative Colitis

By
Siddharth Singh
Jonas Söderling
Anders Forss
Mathias Rask-Andersen
Jonas Halfvarson
Åsa H. Everhov
Jonas F. Ludvigsson
Ola Olén
SWIBREG study group
Malin Olsson
Pär Myrelid
Henrik Hjortswang
Jonas Bengtsson
Hans Strid
Marie Andersson
Susanna Jäghult
Caroline Nordenvall
Charlotte Hedin
Martin Rejler
Olof Grip
Ulrika L Fagerberg
Karl Mårild
Johann Hreinsson
Pontus Karling
September 25, 2026

Jama Network Open

Objective:

To compare long-term outcomes of first-line advanced therapies (infliximab, adalimumab, and vedolizumab) in biologic-naive patients with ulcerative colitis.

Approach:

Study Design: A nationwide, register-based cohort study was conducted using population-based registers in Sweden.
Patient Selection: Biologic-naive patients with UC who initiated infliximab, adalimumab, or vedolizumab from January 1, 2015, to June 30, 2021, were included.
Outcome Measures: Primary outcome was the incidence rate of all-cause hospitalization; secondary outcomes included IBD-related hospitalization, colectomy, corticosteroid use, and therapy switching.

Key Findings:

Vedolizumab and TNF inhibitors showed similar effectiveness in short-term outcomes, but long-term outcomes after treatment decisions and sequencing were not adequately reported in previous studies.
The study utilized comprehensive national health registers for complete follow-up.

Interpretation:

The study aims to provide insights into the long-term outcomes associated with different treatment strategies for UC.

Limitations:

Patient- or physician-reported outcomes, biomarkers of inflammation, and endoscopic reports were not available.
The study design may not account for all confounding factors influencing treatment outcomes.

Conclusion:

The study seeks to clarify the long-term outcomes of different first-line advanced therapies for UC, emphasizing the importance of treatment sequencing.

Comparative Long-Term Outcomes of Vedolizumab and TNF Inhibitors in Patients with Ulcerative Colitis

Objective:

Approach:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Sources:

Original Source(s)

Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis

Related Content

Toward a Rational Use of Probiotics in Very Preterm Infants

Efficacy and safety of Braun enteroenterostomy in patients undergoing pancreatoduodenectomy: a systematic review and meta-analysis

Racial disparities in the rate of same-admission cholecystectomy following biliary pancreatitis